Welcome to our dedicated page for DarioHealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on DarioHealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
DarioHealth's holistic approach offers continuous and customized care, disrupting the traditional episodic approach to healthcare. The company empowers people to adapt their lifestyles for sustainable behavior change, driving exceptional satisfaction, retention, and results. Dario's solutions are globally available to health plans, self-insured employers, care providers, and consumers.
One of DarioHealth's latest achievements includes the acquisition of Twill, Inc., a move that nearly doubles its pro forma revenues for 2023 and enhances its ability to deliver comprehensive digital health solutions. The integration of Twill is expected to create immediate scale, boost gross margins to approximately 80-85% by 2025, and accelerate the path to profitability through significant cost synergies.
Recent news highlights include Dario's partnership with Blue Shield of California to make its award-winning digital health platform, Wellvolution, more accessible to Spanish speakers. This initiative aims to close care gaps in underserved communities by offering personalized solutions for hypertension, diabetes, weight management, and mental health support. Additionally, Dario announced a new contract to provide its cardiometabolic solution to a regional union, further expanding its presence in the public and labor sectors.
DarioHealth's clinical research continuously demonstrates the efficacy of its digital solutions. For instance, a recent study published in the Journal of Internet Medicine (JMIR) showed significant reductions in blood glucose levels and BMI for members using Dario's weight monitoring features. Other studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes highlighted the company's ability to deliver improved health outcomes through integrated solutions.
Financially, DarioHealth reported strong performance in Q1 2024, with revenues of $5.8 million driven by growth in its Business-to-Business-to-Consumer (B2B2C) model. The company continues to launch new customer partnerships and expects further revenue growth throughout 2024.
With a strong cash position and ongoing innovation, DarioHealth is well-prepared to execute its strategy and solidify its leadership in the digital health space.
DarioHealth Corp. (NASDAQ: DRIO) will participate in the Stephens 2021 Best Ideas Conference on March 11, 2021. CEO Erez Raphael and President Rick Anderson will present virtually at 9:00 a.m. ET, with a live webcast available for replay. DarioHealth specializes in digital therapeutics, offering AI-powered solutions for chronic conditions like diabetes and hypertension. The company aims to drive behavioral change through personalized experiences and clinically proven digital tools. For more details, visit dariohealth.com.
DarioHealth Corp. (Nasdaq: DRIO) announced new findings in a clinical study published in JMIR Diabetes, focusing on the impact of digital engagement in managing Type 2 diabetes. The study examined 998 users and revealed that highly engaged users had a 43% decrease in monthly average glucose levels compared to less engaged users. The results emphasize the importance of dynamically personalized engagement over static approaches. DarioHealth aims to integrate behavioral science and AI to enhance user experience and health outcomes, positioning itself as a leader in the digital therapeutics sector.
DarioHealth Corp. (Nasdaq: DRIO) will announce its financial results for Q4 and the full year ended December 31, 2020, on March 9, 2021, at 8:30 am Eastern Time. The conference call will feature leadership including CEO Erez Raphael and CFO Zvi Ben-David. Participants are encouraged to join 10 minutes early. A replay will be available two hours post-call until April 9, 2021. DarioHealth focuses on digital therapeutics, providing evidence-based interventions for those with chronic conditions, including diabetes, through its MyDario™ app.
DarioHealth Corp. (Nasdaq: DRIO) has announced its participation in the Cowen 41st Annual Health Care Conference, set to take place virtually from March 1-4, 2021. CEO Erez Raphael and President Rick Anderson will present on March 1st at 11:00 a.m. ET. DarioHealth is a leader in digital therapeutics, offering AI-powered solutions aimed at managing chronic conditions like diabetes and hypertension. The company emphasizes personalized experiences and clinically proven tools to foster health improvements.
DarioHealth Corp. (Nasdaq: DRIO) is set to participate in the 10th Annual SVB Leerink Global Healthcare Conference from February 24 to 26, 2021. CEO Erez Raphael will host investor meetings during the event, emphasizing Dario's role in the digital therapeutics market. The company is known for its AI-powered solutions aimed at chronic condition management, particularly in diabetes and hypertension. DarioHealth is expanding its reach across various health conditions and geographic markets, focusing on personalized experiences and evidence-based interventions.
DarioHealth Corp. (Nasdaq: DRIO) has announced its acquisition of Upright Technologies Ltd., a digital musculoskeletal (MSK) company, in a stock transaction valued at $31 million. This move expands Dario's digital therapeutic platform, which already serves around 150,000 users, by adding a clinically validated MSK solution that aligns with its focus on chronic conditions. Concurrently, Dario secured $70 million through a private placement to enhance its cash reserves, aiming to fortify its market position. The transaction is expected to close on or about February 7, 2021.
DarioHealth Corp. (Nasdaq: DRIO) announced the addition of Dr. Marilyn Ritholz and Dr. David Horwitz to its Scientific Advisory Board, enhancing its digital therapeutics platform aimed at chronic condition management. The SAB's mission includes leveraging their expertise to improve clinical offerings and market penetration. Dr. Ritholz specializes in diabetes and behavioral health, while Dr. Horwitz has extensive experience in clinical affairs at major diabetes organizations. This strategic move is expected to further advance Dario's AI-driven health solutions, focused on personalized care.
DarioHealth Corp. (NASDAQ: DRIO) has appointed Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships, a new role aimed at enhancing their sales strategy. Ms. Kraut brings extensive experience from her previous role at Omada Health, where she built strong partnerships. Rick Anderson, President of North America, expressed confidence that her expertise will accelerate growth opportunities in 2021 and beyond. The company emphasizes its innovative digital therapeutic solutions aimed at chronic condition management, further strengthening its market position.
DarioHealth Corp. (Nasdaq: DRIO) announced a pivotal agreement to provide its digital therapeutics solution to eligible employees of a subsidiary of a Fortune 500 technology company. This marks Dario's first self-insured employer client via the partnership with Vitality Group. The program, focusing on diabetes and hypertension solutions, will start enrolling members in January 2021. DarioHealth emphasizes its personalized, adaptive healthcare approach, aiming to improve employee health outcomes and reduce care costs.
FAQ
What is the current stock price of DarioHealth (DRIO)?
What is the market cap of DarioHealth (DRIO)?
What is DarioHealth Corp.?
What recent achievements has DarioHealth made?
How does DarioHealth's platform work?
What clinical results support DarioHealth's solutions?
Who are DarioHealth's target customers?
What are the financial prospects for DarioHealth?
What is the significance of DarioHealth's acquisition of Twill?
How does DarioHealth address language barriers in healthcare?
What recent partnerships has DarioHealth announced?
What are the future plans for DarioHealth?
